Quizartinib Effective in Patients With FLT3-ITD–Positive Relapsed, Refractory AML
A phase 2 trial evaluated the safety and efficacy of quizartinib in patients with relapsed/refractory acute myeloid leukemia (AML), compared with salvage chemotherapy.